Du är här


AstraZeneca: Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart...

New sub-analysis to be presented at the European Society of Cardiology
(ESC) congress provides additional evidence of cardiovascular (CV)
benefits associated with longer-term use of Brilinta

AstraZeneca today announced results from a new sub-analysis of data
from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk
reduction in CV death (p=0.0041) from treatment with Brilinta
(ticagrelor) 60mg twice daily, versus placebo, in patients taking
low-dose aspirin but still at high risk of an atherothrombotic event,
a major cause of acute coronary syndrome and CV death.

Patients received Brilinta within two years of having a heart attack
(myocardial infarction, MI) or within one year of stopping
anti-platelet treatment with an adenosine diphosphate (ADP)
inhibitor. The latest results highlight a potential protective CV
benefit associated with longer-term treatment, versus the standard
12-month post-event treatment period, with Brilinta 60mg, and are due
to be presented in full at the ESC Congress in Barcelona, Spain.

The favourable benefit-risk ratio for extended dual anti-platelet
treatment with Brilinta 60mg was suggested earlier in the PEGASUS
trial that provided the data supporting the European Medicines
Agency's approval of Brilinta in the post-MI indication.

Mikael Dellborg, Professor of Cardiology at the University of
Gothenburg and member of the Steering Committee of the PEGASUS-TIMI
54 trial, said: "The conclusion for both clinicians and patients at
high-risk of CV death post-MI is clear: Treatment with Brilinta 60mg,
either as continuation therapy after the initial 12 month post-event
period, or with as limited interruption as possible, is associated
with a clear and favourable benefit-risk ratio for this population of
patients. This new insight is potentially practice-changing, as while
more than seven million people worldwide suffer a heart attack each
year, we know that fewer than half receive adequate long-term
treatment to reduce their risk of further CV events."

The sub-analysis of PEGASUS-TIMI 54 data also showed a risk reduction
of 20% in all causes of death, and 20% in the composite of CV death,
MI or stroke. As expected, major bleeding rates were consistent with
the known safety profile of Brilinta.

Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic
Diseases (CVMD), Global Medicines Development, AstraZeneca, said:
"The Phase III PEGASUS-TIMI 54 trial continues to provide valuable
data and insights with the potential to benefit both healthcare
professionals and their patients. The results reinforce the
importance of our continued investment in the science, helping to
understand better the unique CV and mortality benefits that our
medicines, such as Brilinta, can provide for the millions of patients
living with cardiovascular disease, the leading cause of death

- ENDS -


About Brilinta (ticagrelor)

Brilinta is a direct-acting P2Y12 receptor antagonist in a chemical
class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Brilinta
works by inhibiting platelet activation and has been shown to reduce
the rate of atherothrombotic CV events, such as heart attack or CV
death, in patients with acute coronary syndromes (ACS).

Brilinta, co-administered with aspirin, also known as acetylsalicylic
acid (ASA), is indicated for the prevention of atherothrombotic
events in adult patients with ACS, or for patients with a history of
myocardial infarction (MI) and a high risk of developing an
atherothrombotic event.

About AstraZeneca in Cardiovascular, Renal & Metabolic Diseases (CVMD)

Cardiovascular, renal and metabolic diseases together form one of
AstraZeneca's main therapy areas and platforms for future growth. By
following the science to understand more clearly the underlying links
between the heart, kidney and pancreas, AstraZeneca is investing in a
portfolio of medicines to protect organs and improve outcomes by
slowing disease progression, reducing risks and tackling
co-morbidities. Our ambition is to modify or halt the natural course
of CVMDs and even regenerate organs and restore function, by
continuing to deliver transformative science that improves treatment
practices and CVMD health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Company also is selectively active in the areas
of autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by millions
of patients worldwide.For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.


1. 1. World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet. Accessed 17 August 2017 http://www.who.int/mediacentre/factsheets/fs317/en

Esra Erkal UK/Global +44 203 749 5638
Rob UK/Global +44 203 749 5821
Karen UK/Global +44 203 749 5634
Matt Kent UK/Global +44 203 749 5906
Jacob Lund Sweden +46 8 553 260 20
Michele US +1 302 885 2677

Thomas +44 203 749 5712
Craig Finance, Fixed Income, M&A +44 7881 615 764
Henry Oncology +44 203 749 5797
Mitchell Oncology +1 240 477 3771
Christer Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711
Nick Stone Respiratory; Brilinta +44 203 749 5716
US toll +1 866 381 7277


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.